These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 30694615)
1. Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients. Martin-Malo A; Borchard G; Flühmann B; Mori C; Silverberg D; Jankowska EA ESC Heart Fail; 2019 Apr; 6(2):241-253. PubMed ID: 30694615 [TBL] [Abstract][Full Text] [Related]
2. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia. Anker SD; Colet JC; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Mori C; von Eisenhart Rothe B; Pocock S; Poole-Wilson PA; Ponikowski P; Eur J Heart Fail; 2009 Nov; 11(11):1084-91. PubMed ID: 19875408 [TBL] [Abstract][Full Text] [Related]
3. Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. Gutzwiller FS; Pfeil AM; Comin-Colet J; Ponikowski P; Filippatos G; Mori C; Braunhofer PG; Szucs TD; Schwenkglenks M; Anker SD Int J Cardiol; 2013 Oct; 168(4):3878-83. PubMed ID: 23870642 [TBL] [Abstract][Full Text] [Related]
4. Ferric carboxymaltose in patients with heart failure and iron deficiency. Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P; N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054 [TBL] [Abstract][Full Text] [Related]
5. Ferric Carboxymaltose: A Review in Iron Deficiency. Scott LJ Drugs; 2018 Mar; 78(4):479-493. PubMed ID: 29532438 [TBL] [Abstract][Full Text] [Related]
6. [Anaemia and iron deficiency in clinical practice:from cardiology to gastroenterology and beyond]. Češka R Vnitr Lek; 2014 Dec; 60(12):1033-9. PubMed ID: 25692829 [TBL] [Abstract][Full Text] [Related]
7. Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral? McDonagh T; Macdougall IC Eur J Heart Fail; 2015 Mar; 17(3):248-62. PubMed ID: 25639592 [TBL] [Abstract][Full Text] [Related]
8. [Iron deficiency : a new target in treating chronic heart failure ?]. Borgeaud M; Perrier A Rev Med Suisse; 2016 Oct; 12(535):1747-1751. PubMed ID: 28692214 [TBL] [Abstract][Full Text] [Related]
9. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356 [TBL] [Abstract][Full Text] [Related]
10. Iron substitution in the treatment of chronic heart failure. Gstrein C; Meyer M; Anabitarte P Swiss Med Wkly; 2017; 147():w14453. PubMed ID: 28695549 [TBL] [Abstract][Full Text] [Related]
11. Iron deficiency in heart failure. Dinatolo E; Dasseni N; Metra M; Lombardi C; von Haehling S J Cardiovasc Med (Hagerstown); 2018 Dec; 19(12):706-716. PubMed ID: 30222663 [TBL] [Abstract][Full Text] [Related]
12. Screening, diagnosis and treatment of iron deficiency in chronic heart failure: putting the 2016 European Society of Cardiology heart failure guidelines into clinical practice. McDonagh T; Damy T; Doehner W; Lam CSP; Sindone A; van der Meer P; Cohen-Solal A; Kindermann I; Manito N; Pfister O; Pohjantähti-Maaroos H; Taylor J; Comin-Colet J Eur J Heart Fail; 2018 Dec; 20(12):1664-1672. PubMed ID: 30311713 [TBL] [Abstract][Full Text] [Related]
14. Iron Deficiency in Heart Failure: An Overview. von Haehling S; Ebner N; Evertz R; Ponikowski P; Anker SD JACC Heart Fail; 2019 Jan; 7(1):36-46. PubMed ID: 30553903 [TBL] [Abstract][Full Text] [Related]
15. A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. Comín-Colet J; Rubio-Rodríguez D; Rubio-Terrés C; Enjuanes-Grau C; Gutzwiller FS; Anker SD; Ponikowski P Rev Esp Cardiol (Engl Ed); 2015 Oct; 68(10):846-51. PubMed ID: 25649970 [TBL] [Abstract][Full Text] [Related]
16. Ferric carboxymaltose: a review of its use in iron deficiency. Keating GM Drugs; 2015 Jan; 75(1):101-27. PubMed ID: 25428711 [TBL] [Abstract][Full Text] [Related]
17. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. Bourguignon S; Faller M; Champs FO; Moutier H; Levesque K; Caranhac G; Cohen-Solal A ESC Heart Fail; 2019 Jun; 6(3):559-569. PubMed ID: 31021531 [TBL] [Abstract][Full Text] [Related]
18. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD; Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972 [TBL] [Abstract][Full Text] [Related]
19. Effect of ferric carboxymaltose on hospitalization and mortality outcomes in chronic heart failure: A meta-analysis. Dalal J; Katekhaye V; Jain R Indian Heart J; 2017; 69(6):736-741. PubMed ID: 29174251 [TBL] [Abstract][Full Text] [Related]
20. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]